1. Scrip
  2. >>Focus On Asia
  3. >>China

Novartis/BeiGene Opt For PD-1/TIGIT Combo For NSCLC In US

Defocus On 2L Monotherapy

 
• By Dexter Jie Yan

The two companies have ceased to seek US approval for tislelizumab as a monotherapy for second-line non-small cell lung cancer and are instead seeming to pin their hopes on a combination with BeiGene’s anti-TIGIT antibody ociperlimab in the first-line setting.

Novartis/BeiGene to shift gears
Novartis/BeiGene shift US clinical strategy for non-small cell lung cancer • Source: Shutterstock

Novartis AG and Chinese partner BeiGene, Ltd. are opting to focus on a combination approach for their PD-1 checkpoint inhibitor tislelizumab in non-small cell lung cancer (NSCLC) in the US, after scrapping a plan to file a biologics license application with the US Food and Drug Administration.

On 19 July, Novartis disclosed in its second-quarter report that it had decided not to move forward with the original...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

 
• By Dexter Jie Yan

In first confirmatory randomized controlled trial of any CAR-T therapy in solid tumors, CARsgen’s Claudin 18.2-targeting satri-cel reduced risk of death or disease progression by 63% in Chinese patients with gastric/gastroesophageal junction cancer.

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

More from Focus On Asia

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 
• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.